DUBLIN, Ireland, July 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc AVDL, a company focused on developing FT218 for narcolepsy, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, August 9, 2019, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2019.
To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (international). The conference ID number is 4290467. A live audio webcast can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event.
About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc AVDL is a branded specialty pharmaceutical company. The Company's primary focus is on the development and potential FDA approval for FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, Avadel develops and markets a portfolio of sterile injectable drugs used in the hospital setting. For more information, please visit www.avadel.com.
Contacts: | Michael F. Kanan |
Chief Financial Officer | |
Phone: (636) 449-1844 | |
Email: mkanan@avadel.com | |
Lee Roth | |
Burns McClellan | |
Phone: (212) 213-0006 | |
Email: lroth@burnsmc.com |
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.